JP2018512417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512417A5 JP2018512417A5 JP2017550154A JP2017550154A JP2018512417A5 JP 2018512417 A5 JP2018512417 A5 JP 2018512417A5 JP 2017550154 A JP2017550154 A JP 2017550154A JP 2017550154 A JP2017550154 A JP 2017550154A JP 2018512417 A5 JP2018512417 A5 JP 2018512417A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- binding protein
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003042 antagnostic effect Effects 0.000 claims description 24
- 102000025171 antigen binding proteins Human genes 0.000 claims description 20
- 108091000831 antigen binding proteins Proteins 0.000 claims description 20
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 238000002955 isolation Methods 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 108010029667 pramlintide Proteins 0.000 claims 2
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 2
- GVIYUKXRXPXMQM-BPXGDYAESA-N 221231-10-3 Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(C)C)=O)C1=CC=C(O)C=C1 GVIYUKXRXPXMQM-BPXGDYAESA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010070305 AOD 9604 Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 229940086609 Lipase inhibitor Drugs 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- IMIPDPVHGGHVNH-YWVHRCQQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C3[C@H]21 IMIPDPVHGGHVNH-YWVHRCQQSA-N 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- 229960003611 pramlintide Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 239000002485 serotonin 2C agonist Substances 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- 229940099093 symlin Drugs 0.000 claims 1
- -1 thesofencin Chemical compound 0.000 claims 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 10
- 102100040890 Glucagon receptor Human genes 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142257P | 2015-04-02 | 2015-04-02 | |
| US62/142,257 | 2015-04-02 | ||
| PCT/US2016/025336 WO2016161154A1 (en) | 2015-04-02 | 2016-03-31 | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512417A JP2018512417A (ja) | 2018-05-17 |
| JP2018512417A5 true JP2018512417A5 (enExample) | 2019-05-09 |
| JP6861641B2 JP6861641B2 (ja) | 2021-04-21 |
Family
ID=57006366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550154A Active JP6861641B2 (ja) | 2015-04-02 | 2016-03-31 | グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10752693B2 (enExample) |
| EP (1) | EP3277830A4 (enExample) |
| JP (1) | JP6861641B2 (enExample) |
| KR (1) | KR20170138456A (enExample) |
| CN (1) | CN107614695B (enExample) |
| AU (1) | AU2016242935B2 (enExample) |
| CA (1) | CA2980765A1 (enExample) |
| MX (1) | MX392496B (enExample) |
| WO (1) | WO2016161154A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565559A4 (en) * | 2017-01-09 | 2020-07-08 | Temple University - Of The Commonwealth System of Higher Education | PHARMACEUTICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
| SG11201906682YA (en) | 2017-01-27 | 2019-08-27 | Ngm Biopharmaceuticals Inc | Glucagon receptor binding proteins and methods of use thereof |
| KR102686854B1 (ko) * | 2017-08-09 | 2024-07-18 | 사노피 | 지방간 질환 및 지방간염의 치료에서의 glp-1/글루카곤 수용체 작용제 |
| JP2021514662A (ja) * | 2018-03-08 | 2021-06-17 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｔｉｐ−１抗体及びその使用 |
| CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
| CN111068042B (zh) * | 2018-10-18 | 2023-10-13 | 中山大学 | 一种多肽化合物在制备治疗非酒精性肝病、特发性肺间质纤维化和动脉硬化药物中的应用 |
| WO2020097054A1 (en) * | 2018-11-06 | 2020-05-14 | Georgetown University | Treating non-alcoholic steatohepatitis with cck inhibitors |
| CN115947849A (zh) | 2018-12-21 | 2023-04-11 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
| WO2025178928A1 (en) * | 2024-02-23 | 2025-08-28 | Remd Biotherapeutics, Inc. | Combination therapy for the treatment of obesity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| PA8830501A1 (es) * | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| CN108410868A (zh) * | 2011-09-20 | 2018-08-17 | Ionis制药公司 | Gcgr表达的反义调节 |
| WO2014181229A2 (en) * | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| US10626179B2 (en) * | 2014-06-08 | 2020-04-21 | Remd Biotherapeutics, Inc. | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
-
2016
- 2016-03-31 CA CA2980765A patent/CA2980765A1/en active Pending
- 2016-03-31 MX MX2017012694A patent/MX392496B/es unknown
- 2016-03-31 EP EP16774227.9A patent/EP3277830A4/en not_active Ceased
- 2016-03-31 JP JP2017550154A patent/JP6861641B2/ja active Active
- 2016-03-31 WO PCT/US2016/025336 patent/WO2016161154A1/en not_active Ceased
- 2016-03-31 CN CN201680030380.0A patent/CN107614695B/zh active Active
- 2016-03-31 AU AU2016242935A patent/AU2016242935B2/en not_active Ceased
- 2016-03-31 KR KR1020177031693A patent/KR20170138456A/ko not_active Ceased
- 2016-03-31 US US15/563,162 patent/US10752693B2/en active Active
-
2020
- 2020-07-14 US US16/928,441 patent/US20200339697A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512417A5 (enExample) | ||
| US10906965B2 (en) | Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1 | |
| TWI605061B (zh) | 會結合及阻斷表現在骨髓細胞上觸發受體－１（ｔｒｅｍ－１）之抗體 | |
| CN111183159B (zh) | 靶向cd137的抗体及其使用方法 | |
| US10941198B2 (en) | Human anti-IFN-α antibodies | |
| JP2017521998A (ja) | 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法 | |
| CN105980556A (zh) | 人抗il－33中和单克隆抗体 | |
| JP2020534830A5 (enExample) | ||
| BRPI0719762B8 (pt) | anticorpo humano isolado, composição, polinucleotídeo isolado, vetor de expressão, microrganismo isolado, método para fabricação de um anticorpo, e, uso de um anticorpo | |
| SG191716A1 (en) | Neutralizing anti-ccl20 antibodies | |
| JPWO2019137548A5 (enExample) | ||
| AU2022252731B2 (en) | Protein Binders For iRhom2 | |
| US10975144B2 (en) | CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody | |
| RU2014106933A (ru) | Способы и композиции для лечения аутоиммунных и воспалительных заболеваний | |
| CN110214027A (zh) | 抗人tim-3抗体及其使用方法 | |
| CN120248120A (zh) | 靶向pdl1的抗体及其使用方法 | |
| JP2024533488A (ja) | 抗ヒトｃｄ３抗体及びその応用 | |
| KR20180109977A (ko) | Il-17c에 대한 항체 | |
| US12252541B2 (en) | Anti-BCMA antibody and use thereof | |
| US20230242640A1 (en) | ANTI-SIRPg Compounds | |
| WO2025232057A1 (zh) | 可结合人cd137单克隆抗体或其功能性片段及其应用 | |
| RU2022104587A (ru) | Система химерных антигенных рецепторов и ее применение | |
| RU2021119549A (ru) | Способы и фармацевтические композиции для усиления cd8+ t-клеточных иммунных ответов у субъектов, страдающих от рака |